Home > Boards > US OTC > Biotechs > NorthWest Biotherapeutics Inc. (NWBO)

Does MGMT methylated REALLY need TERT methylated to

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
abeta Member Profile
Member Level 
Followed By 21
Posts 2,214
Boards Moderated 0
Alias Born 02/06/17
160x600 placeholder
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 10/16/2020 6:59:18 PM
Prospectus Filed Pursuant to Rule 424(b)(5) (424b5) Edgar (US Regulatory) - 10/13/2020 9:31:10 AM
Amended Current Report Filing (8-k/a) Edgar (US Regulatory) - 9/15/2020 5:14:31 PM
SA Breaking News: ALYI - Alternet Systems revenue surging with new potential customers InvestorsHub NewsWire - 9/14/2020 10:10:04 AM
Traders News Source Identifies Tomorrows NASDAQ's InvestorsHub NewsWire - 9/3/2020 8:45:00 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 9/1/2020 3:24:29 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 8/20/2020 4:52:41 PM
Quarterly Report (10-q) Edgar (US Regulatory) - 8/10/2020 4:44:16 PM
Prospectus Filed Pursuant to Rule 424(b)(5) (424b5) Edgar (US Regulatory) - 8/7/2020 5:27:35 PM
Prospectus Filed Pursuant to Rule 424(b)(5) (424b5) Edgar (US Regulatory) - 6/26/2020 5:07:03 PM
Quarterly Report (10-q) Edgar (US Regulatory) - 6/24/2020 6:02:25 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 6/8/2020 5:02:02 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 6/4/2020 5:12:40 PM
Prospectus Filed Pursuant to Rule 424(b)(5) (424b5) Edgar (US Regulatory) - 5/29/2020 5:28:18 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 5/27/2020 5:15:15 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 5/20/2020 5:06:06 PM
Notification That Quarterly Report Will Be Submitted Late (nt 10-q) Edgar (US Regulatory) - 5/12/2020 4:12:38 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 4/23/2020 5:10:20 PM
Cannabis? CBD? That's Old News, A New Sector Bull Run Has Begun InvestorsHub NewsWire - 4/16/2020 8:00:00 AM
Prospectus Filed Pursuant to Rule 424(b)(5) (424b5) Edgar (US Regulatory) - 4/9/2020 5:28:45 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 4/1/2020 4:41:56 PM
Proxy Statement (definitive) (def 14a) Edgar (US Regulatory) - 3/27/2020 2:47:39 PM
Annual Report (10-k) Edgar (US Regulatory) - 3/16/2020 5:01:48 PM
Prospectus Filed Pursuant to Rule 424(b)(5) (424b5) Edgar (US Regulatory) - 2/24/2020 5:07:15 PM
PURA ALERT - MACD Cross Pushing $0.039 50 Day MA With $0.35 Analyst TGT Recommendation InvestorsHub NewsWire - 2/10/2020 12:50:46 PM
abeta Member Level  Wednesday, 09/23/20 11:59:12 AM
Re: None
Post # of 323414 
Does MGMT methylated REALLY need TERT methylated to
have an effect

Conclusions:
The prognostic value of TERT promoter mutation may be modulated by MGMT methylation status.

Not all MGMT-methylated GBM patients may benefit from TMZ;

it is possible that only TERT-mutated GBM with MGMT methylation, in particular, may respond.

2020 - Sept
The interaction between TERT promoter mutation and MGMT promoter methylation on overall survival of glioma patients: a meta-analysis

https://pubmed.ncbi.nlm.nih.gov/32957941/

TERT and DCVAX
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6422384/


https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5337853/


Quote:
How Do we Find Patients Who Will Respond?

Dr. Liau has long experience with dendritic cell cancer vaccines. She injected her first patient in 1999. In the phase 1/2 trials of DCVax-L which were the basis for the planning of the phase 3 DCVax-L trial, about 30% of patients are still alive. The question is how can these patients who apparently are so responsive to DCVax-L be identified prospectively?

Glioblastomas are Heterogeneous

She says that glioblastomas are heterogeneous as the disease can emanate from quite different genetic mutations which may determine which subset(s) of patients who benefit. She cited mesenchymal vs. proneural. MGMT, IDH, 1p19q, TERT as examples. There are also other predictors such as the degree of resection. The challenge is to understand what biomarkers characterize the 20% to 30% of patients who receive great benefit?




https://smithonstocks.com/northwest-biotherapeutics-dcvax-l-viewed-through-the-eyes-of-dr-linda-liau-lead-investigator-on-the-phase-3-trial-of-dcvax-l-nwbo-0-35-buy/


Management of glioblastoma: State of the art and future directions
https://acsjournals.onlinelibrary.wiley.com/doi/full/10.3322/caac.21613












Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist
Consent Preferences